슬롯총판 ㎰ 31.ruk737.top ㎰ 바다이야기기계
페이지 정보
작성자 영규용남 작성일25-08-20 18:51 조회31회 댓글0건관련링크
-
http://95.rzc216.top
25회 연결
-
http://34.rhq291.top
26회 연결
본문
【4.ruk737.top】
PanGen CI. (Image=PanGen)
PanGen Biotech announced on Wednesday its second quarter revenue of 3.49 billion won and operating profit of 833 million won up 5 1주택자 디딤돌대출 3.7 percent and turned a profit respectively from a year earlier.
PanGen Biotech’s revenue on Erythropoietin (EPO) biosimilar recorded 76% growth in the second quarter of this yea 화의절차 r compared to the same period last year.
PanGen Biotech recorded 368% revenue growth for Contract Development and Manufacturing Organization (CDMO) business, and 77% revenue growth on runni 무지개론 대출 ng royalty, year-over-year. The company’s order backlog totaled 5.3 billion won as of June 30, including a Contract Manufacturing Organization (CMO) agreement worth 1.9 billion won with CHA Vaccine In 새마을금고 비과세 stitute in the second quarter.
The company’s operating profit rose dramatically due to increase in exports on EPO biosimilar and royalty revenue. For six months ended June 30, 2025, PanGen B 영국성적 iotech reported its revenue of 6.93 billion won marking a 20.6% year over year increase and operating profit of 1.53 billion won, turning into a profit compared to the loss of 36 million won same period last year.
PanGen Biotech showed strong growth throughout all business areas including EPO biosimilar and Contract Development Organization (CDO) business.
For EPO biosimilar business, PanGen Biotech showed strong overseas sales in ASEAN countries, including Malaysia and Philippines, and developed full-fledged sale in Saudi Arabia and Turkiye. PanGen Biotech expects continued EPO revenue growth in the Middle East and Africa.
PanGen Biotech provides CDMO service for biopharmaceuticals and manufactures and sells biosimilar based on its expertise in developing original cell lines and establishing processes for biopharmaceutical production. Equipped with a good manufacturing practice (GMP) facility, PanGen Biotech has continuously received CMO orders including the order from Huonslab last year.
CEO of PanGen Biotech Jaeseung Yoon said “Continuing to build upon our momentum PanGen Biotech will deliver stronger sales by strengthening overseas marketing for EPO biosimilar in the second half of this year. We will continue to show improvement in performance by focusing on CDMO expansions.”
신민준 (adonis@edaily.co.kr)
슬롯총판 ㎰ 91.ruk737.top ㎰ 바다이야기기계
슬롯총판 ㎰ 89.ruk737.top ㎰ 바다이야기기계
슬롯총판 ㎰ 77.ruk737.top ㎰ 바다이야기기계
슬롯총판 ㎰ 38.ruk737.top ㎰ 바다이야기기계
바로가기 go !! 바로가기 go !!
릴게임백경 릴게임주소 황금성 게임 다운로드 오징어 릴게임 릴게임연타 슬롯머신 확률 황금성3게임연타 야마토2 인터넷빠찡꼬 모바일야마토게임 모바일 야마토 황금성게임방법 슬롯무료체험 오리 지날야마토 바다이야기 파칭코 뉴야마토 신규릴게임 잘터지는 슬롯 슬롯사이트 순위 바다이야기사이트먹튀 체리게임주소 카지노 슬롯머신 잭팟 야마토 2 다운로드 오션파라 다이스하는방법 황금성게임장 릴게임 꽁머니 바다이야기 기프트 전환 무료 슬롯 머신 다운 받기 바다이야기 사이트 파칭코슬롯 알라딘오락실 체리마스터 다운로드 릴게임횡금성 황금성배당줄 릴게임5만릴짱 슬롯머신 프로그램 오리지날야마토연타예시 프라그마틱 슬롯 조작 야마토창공 꽁머니릴게임 무료슬롯체험 신천지게임하는곳 씨엔조이 릴게임 해물어 잭팟 온라인파칭코 온라인백경 예시 하이클래스릴게임 실시간파워볼 온라인 슬롯 머신 게임 빠칭코 슬롯머신 메타슬롯 Pg 소프트 무료 체험 블랙홀3D 릴게임 카지노 슬롯머신 규칙 슬롯사이트순위 릴게임설치 다빈치릴게임다운로드 로또달팽이 슬롯 무료스핀 강원랜드 슬롯머신 규칙 골드몽릴게임 릴게임5만 프라그마틱 슬롯 조작 일본야마토게임 파라다이스오션 황금성포커 릴게임임대 황금성게임 야마토 릴게임 바다이야기파일 바다이야기 게임 다운로드 황금성나비 바다이야기 게임 방법 스핀모바게임랜드 뽀빠이놀이터릴게임 황금성오락실 바다이야기노무현 알라딘게임예시 신규릴게임 온라인 슬롯머신 신천지게임사이트 릴게임다운로드 안전 슬롯사이트 바다이야기릴게임 백경온라인 한게임머니파는곳 오션파라 다이스예시 무료온라인게임 황금성게임공략 법 바다이야기환전가능 황금성 게임 장주소 무료게임다운로드 무료온라인게임 바다이야기 먹튀 돈 받기 릴게임황금포카성 신천지릴게임장주소 모바일 바다이야기 일본야마토 PC 릴게임 릴게임 사이트 도메인 한게임머니파는곳 야마토 2 온라인 게임 10원야 마토 야마토 빠칭코 무료게임다운로드 바다 이야기 다운 신천기릴게임 바다이야기 게임장 다빈치무료릴게임 황금성동영상 온라인 슬롯 배팅법 바다이야기사이트먹튀 손오공게임다운 오션파라 다이스하는방법 바다이야기5 오션파라다이스 예시 손오공바다이야기 다모아릴게임 스위피릴게임 황금성게임다운로드후기 jQuery 슬롯 머신 슬롯나라무료 강원랜드 슬롯머신 가격 [Shin-Min Joon, Edaily Reporter] PanGen Biotech of Huons Group reported robust quarterly revenue and turned a profit in the second quarter of this year.PanGen CI. (Image=PanGen)
PanGen Biotech announced on Wednesday its second quarter revenue of 3.49 billion won and operating profit of 833 million won up 5 1주택자 디딤돌대출 3.7 percent and turned a profit respectively from a year earlier.
PanGen Biotech’s revenue on Erythropoietin (EPO) biosimilar recorded 76% growth in the second quarter of this yea 화의절차 r compared to the same period last year.
PanGen Biotech recorded 368% revenue growth for Contract Development and Manufacturing Organization (CDMO) business, and 77% revenue growth on runni 무지개론 대출 ng royalty, year-over-year. The company’s order backlog totaled 5.3 billion won as of June 30, including a Contract Manufacturing Organization (CMO) agreement worth 1.9 billion won with CHA Vaccine In 새마을금고 비과세 stitute in the second quarter.
The company’s operating profit rose dramatically due to increase in exports on EPO biosimilar and royalty revenue. For six months ended June 30, 2025, PanGen B 영국성적 iotech reported its revenue of 6.93 billion won marking a 20.6% year over year increase and operating profit of 1.53 billion won, turning into a profit compared to the loss of 36 million won same period last year.
PanGen Biotech showed strong growth throughout all business areas including EPO biosimilar and Contract Development Organization (CDO) business.
For EPO biosimilar business, PanGen Biotech showed strong overseas sales in ASEAN countries, including Malaysia and Philippines, and developed full-fledged sale in Saudi Arabia and Turkiye. PanGen Biotech expects continued EPO revenue growth in the Middle East and Africa.
PanGen Biotech provides CDMO service for biopharmaceuticals and manufactures and sells biosimilar based on its expertise in developing original cell lines and establishing processes for biopharmaceutical production. Equipped with a good manufacturing practice (GMP) facility, PanGen Biotech has continuously received CMO orders including the order from Huonslab last year.
CEO of PanGen Biotech Jaeseung Yoon said “Continuing to build upon our momentum PanGen Biotech will deliver stronger sales by strengthening overseas marketing for EPO biosimilar in the second half of this year. We will continue to show improvement in performance by focusing on CDMO expansions.”
신민준 (adonis@edaily.co.kr)
댓글목록
등록된 댓글이 없습니다.